Cancer Res Treat.  2004 Feb;36(1):68-71.

Intrapleural Chemotherapy with Cisplatin and Cytarabine in the Management of Malignant Pleural Effusion

• Kim KW
• Park SY
• Kim MS
• Kim SC
• Lee EH
• Shin SY
• Lee JH
• Kweon JB
• Park K

Abstract

PURPOSE
The purpose of this study was to evaluate the efficacy of intrapleural chemotherapy (IPC) with cisplatin and cytarabine in the management of malignant pleural effusion (MPE) from non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS: A prospective analysis was carried out on 40 patients with pathologically proven MPE from NSCLC who had received IPC. A single dose of cisplatin 100 mg/m2 plus cytarabine 1200 mg/m2 in 250 ml normal saline was instilled into the pleural space via a chest tube and drained 4 hours later. Patients were evaluated for toxicities and responses at 1, 2, & 3 weeks and then at monthly intervals if possible. Systemic chemotherapy was administered, if the patient agreed to receive it, after achieving complete control (CC) of MPE. RESULTS: The median duration of chest tube insertion for drainage was 7 (3~32) days. Among the assessable 37 patients, CC and partial control (PC) were 32 (86.5%) and 4 (10.8%) patients, respectively (overall response rate 97.3%). The median duration of response was 12 months (2~23) and there were only two relapses of IPC after achieving CC. Among the 35 patients who were assessable until they died, 28 patients (80.0%) maintained CC until the last follow-up. There was only one toxic death and the toxicities of IPC, versus the results obtained, were deemed acceptable. CONCLUSION: The procedures were tolerable to the patients and chemotherapy-induced complications were at an acceptable level. The outcome of this trial indicates that IPC has a superior and long lasting treatment response in the management of patients with MPE from NSCLC.

Keyword

Pleural effusion; Intrapleural chemotherapy; Cisplatin; Cytarabine

MeSH Terms

Chest Tubes
Cisplatin*
Cytarabine*
Drainage
Drug Therapy*
Follow-Up Studies
Humans
Lung Neoplasms
Pleural Effusion
Pleural Effusion, Malignant*
Prospective Studies
Recurrence
Cisplatin
Cytarabine

Reference

1. Hausheer FH, Yarbro JW. Diagnosis and treatment of malignant pleural effusion. Semin Oncol. 1985; 12:54–75. PMID: 2579439.

2. Ruckdeschel JC. Management of malignant pleural effusion: An overview. Semin Oncol. 1988; 15(suppl 3):24–28. PMID: 3293215.

3. Moores DWO. Malignant pleural effusion. Semin Oncol. 1991; 18(suppl 2):59–61. PMID: 1704153.

4. Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med. 1994; 120:56–64. PMID: 8250457.

5. Rusch VW, Figlin R, Godwin D, Piantadosi S. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: A lung cancer study group trial. J Clin Oncol. 1991; 9:313–319. PMID: 1988578.

6. Figlin R, Mendoza E, Piantadosi S, Rusch V. Intrapleural chemotherapy without pleurodesis for malignant pleural effusions: LCSG Trial 861. Chest. 1994; 106(suppl):363s–366s. PMID: 7988265.

7. Aasebo U, Norum J, Sager G, Slordal L. Intrapleurally instilled mitoxantrone in metastatic pleural effusions: A phase II study. J Chemother. 1997; 9:106–111. PMID: 9176748.

8. Perng RP, Chen YM, Wu MF, Chou KC, Lin WC, Liu JM, et al. Phase II trial of intrapleural paclitaxel injection for non-small-cell lung cancer patients with malignant pleural effusions. Respir Med. 1988; 92:473–479. PMID: 9692108.

9. Rubinson Rm, Bolooki H. Intrapleural tetracycline for control of malignant pleural effusion: A preliminary report. South Med J. 1972; 65:847–849. PMID: 5038178.

10. Gravelyn TR, Michelson MK, Gross BH, Sitrin RG. Tetracycline pleurodesis for malignant pleural effusions: A ten-year retrospective study. Cancer. 1987; 59:1973–1977. PMID: 2436744.

11. Hartman DI, Gaither JM, Kesler KA, Mylet DM, Brown JW, Mathus PN. Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. J Thorac Cardiovasc Surg. 1993; 105:743–748. PMID: 7682268.

12. Mansson T. Treatment of malignant pleural effusion with doxycycline. Scand J Infect Dis Suppl. 1988; 53:29–34. PMID: 3166542.

13. Hillerdal G, Kiviloog J, Nou E, Steinholtz L. Corynebacterium parvum in malignant pleural effusion: A randomized prospective study. Eur J Respir Dis. 1986; 69:204–206. PMID: 2430825.

14. Paladine W, Cunningham TJ, Sponzo R, Donavan M, Olson K, Hoton J. Intacavitay bleomycin in the management of malignant effusions. Cancer. 1976; 38:1903–1908. PMID: 62609.

15. Lim HY, Kim JH, Park YH, Chung HC, Choi JJ, CHoi SG, Kim HG, Choi JH, Yoo NC, Koh EH, Chang J, Roh JK, Kim SK, Lee WY, Youn JK, Kim BS, Kim JJ. Intrapleural instillation of OK-432 for malignant pleural effusion. J Korean Cancer Assoc. 1992; 24:47–55.

16. Markman M, Cleary S, King ME, Howell SB. Cisplatin and cytarabine administered intrapleurally as treatment of malignant pleural effusions. Med Pediatr Oncol. 1985; 13:191–193. PMID: 4040205.

17. Aitini E, Cavazzini G, Pasquini E, et al. Treatment of primary of metastatic pleural effusion with intracavitary cytosine arabinoside and cisplatin. A phase II study. Acta Oncol. 1994; 33:191–194. PMID: 8204275.